Drug Trial News

RSS

Novel therapy found to be safe and well-tolerated in patients with bone marrow cancer

Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial.

12 Dec 2021

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

12 Dec 2021

NRG Oncology CC004 trial: Bupropion does not improve sexual desire for female cancer survivors

Despite preliminary supporting evidence that the dopaminergic agent bupropion might improve sexual desire for female cancer survivors, the NRG Oncology CC004 clinical trial determined that bupropion did not improve outcomes when compared to a placebo.

10 Dec 2021

Biologic agent dupilumab effective in improving asthma exacerbations and lung function, study shows

A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.

9 Dec 2021

Positive results from Phase 3 study of Medicago’s plant-based COVID-19 vaccine candidate announced

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

9 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination

A new study supports the hypothesis that heterologous vaccination can provide an increased immune response against virus infection, supporting several other studies that have indicated similar events.

5 Dec 2021

SARS-CoV-2 infection risks increase with time in fully vaccinated adults

A recent study describes the association between time elapsed since the second dose of the Pfizer-BioNTech BNT162b2 vaccine and risk of COVID-19.

1 Dec 2021

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Researchers employ a structure-guided approach for the development of a series of ACE2-Fc variants using human IgG1 or IgG3 backbone.

1 Dec 2021

Fourth shot of Moderna COVID vaccine improves Delta variant neutralization in kidney transplant patients

New research suggests that a fourth dose of the mRNA-1273 vaccine in kidney transplant recipients improves Delta variant serum neutralization.

1 Dec 2021

Study shows long-term safety and biologic activity of golodirsen in DMD patients

This first-in-human study of golodirsen showed its long-term safety and biologic activity in patients with Duchenne Muscular Dystrophy (DMD). The approved exon-skipping therapy is designed to enable the production of functional dystrophin proteins, as described in the peer-reviewed journal Nucleic Acid Therapeutics.

1 Dec 2021

Teriflunomide tempers lesion growth in pediatric patients with multiple sclerosis

There are few treatment options for children with multiple sclerosis - a condition in which the immune system attacks the protective covering of nerves in the brain and spinal cord - and most therapies for the disease have not been tested in children.

30 Nov 2021

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

In a new study, published on the bioRxiv* preprint server, scientists aimed to determine the reaction of the molnupiravir parent drug (NHC) to different SARS-CoV-2 Variants of Concern (VoCs). They also sought to establish the therapeutic window in a human lung cell model.

29 Nov 2021

$Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients$

Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients

A research team from the Graduate School of Medicine at Osaka University has started an investigator-initiated clinical trial of sodium astatine ([211At]NaAt) injection for refractory differentiated thyroid cancer patients.

29 Nov 2021

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

25 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

Previous
1
...
46
47
48
49
50
51
52
...
1149
Next

Drug Trial News

Novel therapy found to be safe and well-tolerated in patients with bone marrow cancer

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

NRG Oncology CC004 trial: Bupropion does not improve sexual desire for female cancer survivors

Biologic agent dupilumab effective in improving asthma exacerbations and lung function, study shows

Positive results from Phase 3 study of Medicago’s plant-based COVID-19 vaccine candidate announced

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination

SARS-CoV-2 infection risks increase with time in fully vaccinated adults

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Fourth shot of Moderna COVID vaccine improves Delta variant neutralization in kidney transplant patients

Study shows long-term safety and biologic activity of golodirsen in DMD patients

Teriflunomide tempers lesion growth in pediatric patients with multiple sclerosis

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients

Study finds atazanavir inhibits main SARS-CoV-2 protease

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

CoronaVac vaccine booster strengthens protection against SARS-CoV-2

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News